Home
/
Beam Therapeutics Inc.
/
Financials
/
Quarterly
Beam Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Beam Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2021
Mar 31, 2021
$6.0K
May 11, 2021
Q3
2020
Sep 30, 2020
$6.0K
Nov 10, 2020
Q2
2020
Jun 30, 2020
$6.0K
Aug 12, 2020
Q1
2021
Mar 31, 2020
$6.0K
May 11, 2021
Q3
2020
Sep 30, 2019
$6.0K
Nov 10, 2020
Q2
2020
Jun 30, 2019
$6.0K
Aug 12, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$9.70M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$8.47M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$7.47M
May 6, 2025
Q3
2025
Sep 30, 2024
$14.27M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$11.77M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$7.41M
May 6, 2025
Q3
2024
Sep 30, 2023
$17.19M
Nov 5, 2024
Q2
2024
Jun 30, 2023
$20.12M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$24.21M
May 7, 2024
Q3
2023
Sep 30, 2022
$15.80M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$16.65M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$8.43M
May 10, 2023
Q3
2022
Sep 30, 2021
$763.0K
Nov 7, 2022
Q2
2022
Jun 30, 2021
$6.0K
Aug 9, 2022
Q1
2022
Mar 31, 2021
$6.0K
May 9, 2022
Q3
2021
Sep 30, 2020
$6.0K
Nov 8, 2021
Q2
2021
Jun 30, 2020
$6.0K
Aug 10, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($112.73M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($102.29M)
Aug 5, 2025
Q3
2025
Jun 30, 2025
($102.29M)
Nov 4, 2025
Q2
2025
Mar 31, 2025
($109.27M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($109.27M)
May 6, 2025
Q3
2025
Mar 31, 2025
($109.27M)
Nov 4, 2025
Q3
2025
Sep 30, 2024
($96.67M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($91.05M)
Aug 5, 2025
Q3
2025
Jun 30, 2024
($91.05M)
Nov 4, 2025
Q1
2025
Mar 31, 2024
($98.67M)
May 6, 2025
Q2
2025
Mar 31, 2024
($98.67M)
Aug 5, 2025
Q3
2025
Mar 31, 2024
($98.67M)
Nov 4, 2025
Q3
2024
Sep 30, 2023
($96.09M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($82.78M)
Aug 6, 2024
Q3
2024
Jun 30, 2023
($82.78M)
Nov 5, 2024
Q1
2024
Mar 31, 2023
($96.46M)
May 7, 2024
Q2
2024
Mar 31, 2023
($96.46M)
Aug 6, 2024
Q3
2024
Mar 31, 2023
($96.46M)
Nov 5, 2024
Q3
2023
Sep 30, 2022
($109.58M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($71.95M)
Aug 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($126.81M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($120.15M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($119.29M)
May 6, 2025
Q3
2025
Sep 30, 2024
($106.50M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($104.90M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($104.13M)
May 6, 2025
Q3
2024
Sep 30, 2023
($108.27M)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($102.15M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($98.93M)
May 7, 2024
Q3
2023
Sep 30, 2022
($91.30M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($81.97M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($76.23M)
May 10, 2023
Q3
2022
Sep 30, 2021
($69.63M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($58.97M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($200.37M)
May 9, 2022
Q3
2021
Sep 30, 2020
($37.32M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($26.29M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($28.36M)
May 11, 2021
Q3
2020
Sep 30, 2019
($18.02M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($17.65M)
Aug 12, 2020